PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22399088-10 2011 Conversely, LPO content decreased by 18.97% and 24.06% and MPO level by 42.86% and 18.66% after FK-506 and CsA treatment. Tacrolimus 96-102 myeloperoxidase Rattus norvegicus 59-62 29553465-18 2018 Myeloperoxidase and malondialdehyde levels were significantly correlated between the EGb761 and FK506 groups, even at lower levels in the EGb761 group (p<0.001). Tacrolimus 96-101 myeloperoxidase Rattus norvegicus 0-15 17202747-8 2007 The increases in MPO activity and TBARS were also significantly attenuated by tacrolimus. Tacrolimus 78-88 myeloperoxidase Rattus norvegicus 17-20 17542013-7 2007 Severity of colitis as determined by myeloperoxidase activity was found to have linear correlation to changes in tacrolimus degradation (R2 = 0.8299). Tacrolimus 113-123 myeloperoxidase Rattus norvegicus 37-52 19952532-5 2009 Pretreatment with tacrolimus also produced significant (p<0.05) reduction in TBARS, total calcium, TNF-alpha, IL-8 and MPO whereas it showed an increase in GSH level at higher dose. Tacrolimus 18-28 myeloperoxidase Rattus norvegicus 122-125 17367747-4 2007 RESULTS: Radiographic, enzymatic (myeloperoxidase) and histological analysis revealed that Tacrolimus reduced the severity of periodontitis. Tacrolimus 91-101 myeloperoxidase Rattus norvegicus 34-49 15212998-6 2004 Tacrolimus also significantly decreased microglial activation at 8 h and inflammatory markers (cytokine-induced neutrophil chemoattractant and myeloperoxidase [MPO] activity) at 24 h after reperfusion in the ischemic cortex but not in the caudate putamen. Tacrolimus 0-10 myeloperoxidase Rattus norvegicus 143-158 15783066-6 2005 RESULTS: The clinical activity score and myeloperoxidase activity decreased after the administration of all FK506-containing formulations. Tacrolimus 108-113 myeloperoxidase Rattus norvegicus 41-56 15212998-6 2004 Tacrolimus also significantly decreased microglial activation at 8 h and inflammatory markers (cytokine-induced neutrophil chemoattractant and myeloperoxidase [MPO] activity) at 24 h after reperfusion in the ischemic cortex but not in the caudate putamen. Tacrolimus 0-10 myeloperoxidase Rattus norvegicus 160-163 10385251-12 1999 Tacrolimus (100 microg kg(-1), 5 min after splanchnic arteries occlusion) increased survival rate (SAO + Tacrolimus = 100% at 4 h of reperfusion), reverted the marked hypotension, reduced serum TNF-alpha (15+/-3 U ml(-1)), ameliorated leukopenia, reduced ileal MPO (0.9+/-0.01 U g(-1) tissue), restored to control values the hyporeactivity to PE. Tacrolimus 0-10 myeloperoxidase Rattus norvegicus 261-264 15035807-11 2003 The myeloperoxidase enzyme level was significantly increased in carrageenan-treated animals, which was significantly reversed by FK506 treatment. Tacrolimus 129-134 myeloperoxidase Rattus norvegicus 4-19 11986604-8 2002 The protective effects of cyclosporine and tacrolimus treatment before reperfusion correlated with 42% and 43% reductions in tissue polymorphonuclear leukocyte (myeloperoxidase) content (P <.008) and marked reductions in bronchoalveolar lavage leukocyte accumulation (P <.01). Tacrolimus 43-53 myeloperoxidase Rattus norvegicus 161-176 9374148-7 1997 The increase in accumulation of neutrophils, and MDA and MPO levels (which were induced by ischemia) observed 1 and 24 hours after flap elevation was diminished by FK506 pretreatment. Tacrolimus 164-169 myeloperoxidase Rattus norvegicus 57-60 9655420-11 1998 Flap necrosis and the increase in malondialdehyde, myeloperoxidase, and neutrophil infiltration were improved by FK506 pretreatment, a neutrophil modulating agent. Tacrolimus 113-118 myeloperoxidase Rattus norvegicus 51-66 7512015-9 1994 Water-immersion stress significantly increased myeloperoxidase activity in gastric mucosa, and FK506 reduced the increase in myeloperoxidase activity induced by stress. Tacrolimus 95-100 myeloperoxidase Rattus norvegicus 125-140 7544633-8 1995 Activities of myeloperoxidase and concentrations of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), PGF2 alpha and PGE2 in colonic tissue increased significantly following induction of experimental colitis, however, FK506 did not affect these changes. Tacrolimus 219-224 myeloperoxidase Rattus norvegicus 14-29 7685932-7 1993 FK506 and CsA-treated animals had better survival and diminished neutrophil liver infiltration, as well as MPO and MDA levels. Tacrolimus 0-5 myeloperoxidase Rattus norvegicus 107-110